Plato Investment Management Ltd Grows Holdings in Amgen Inc. $AMGN

Plato Investment Management Ltd increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 12.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,304 shares of the medical research company’s stock after purchasing an additional 2,258 shares during the period. Plato Investment Management Ltd’s holdings in Amgen were worth $5,686,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Legacy Investment Solutions LLC purchased a new stake in Amgen during the 2nd quarter valued at approximately $27,000. Evelyn Partners Investment Management LLP purchased a new position in shares of Amgen in the 2nd quarter valued at approximately $32,000. Howard Hughes Medical Institute purchased a new stake in shares of Amgen during the second quarter worth approximately $32,000. Quaker Wealth Management LLC lifted its holdings in shares of Amgen by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after purchasing an additional 240 shares during the period. Finally, Cloud Capital Management LLC purchased a new position in Amgen in the 3rd quarter valued at $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

AMGN opened at $384.20 on Friday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12. The stock has a market cap of $206.88 billion, a P/E ratio of 27.00, a P/E/G ratio of 3.90 and a beta of 0.46. The stock’s 50 day simple moving average is $334.45 and its 200 day simple moving average is $311.49. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.99.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the business earned $5.31 earnings per share. Amgen’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.6%. Amgen’s payout ratio is 66.90%.

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. The trade was a 11.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.76% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on AMGN shares. Cantor Fitzgerald upped their price objective on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday. Morgan Stanley increased their price target on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a report on Wednesday. Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective on the stock. in a report on Tuesday, January 20th. Leerink Partners increased their target price on Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $351.65.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.